Semaglutide reduces drinking in adults with alcohol use disorder and obesity
The Brown University Psychopharmacology Update · 2026-08 · 37 (8) · 1-6
DOI: 10.1002/pu.31472 ↗At a glance
Journal article in The Brown University Psychopharmacology Update, published online on 2026-06-28.
Topics: Sucht und Abhängigkeit
Abstract (original language)
Weekly doses of semaglutide were more effective than placebo in reducing heavy drinking in patients with alcohol use disorder (AUD) and comorbid obesity, a 26‐week trial has found. Semaglutide also resulted in improvement in several metabolic measures, including weight and body mass index (BMI). Study results were published online May 2, 2026 in The Lancet .
Cite
APA
(2026). Semaglutide reduces drinking in adults with alcohol use disorder and obesity. The Brown University Psychopharmacology Update, 37(8), 1-6. https://doi.org/10.1002/pu.31472
Vancouver
Semaglutide reduces drinking in adults with alcohol use disorder and obesity. The Brown University Psychopharmacology Update. 2026;37(8):1-6. doi:10.1002/pu.31472
BibTeX
@article{euvimed2026,
title = {Semaglutide reduces drinking in adults with alcohol use disorder and obesity},
journal = {The Brown University Psychopharmacology Update},
year = {2026},
volume = {37},
number = {8},
pages = {1--6},
doi = {10.1002/pu.31472}
}
EUVIMED